Lexaria Bioscience Corp — Quarterly Financial Statistics (NASDAQ:LEXX) | MetaTrader

Open full chart

Financials

Overview Relatórios Statistics Dividends

Quarterly Annual

Cash from operating activities -1.27 M-1.89 M-2.73 M-1.5 M-3.58 M-2.64 M-984.1 K -8.71 M Cash from investing activities -22 K-69.59 K-37.8 K-27.89 K-19.44 K-157.88 K-5 099 -210.31 K Cash from financing activities 5.04 M—4.35 M11.72 K1.69 M03.47 M 5.17 M Free cash flow -1.29 M-1.96 M-2.75 M-1.5 M-3.58 M-2.64 M-989.2 K -8.71 M

Notícias

Acionistas da Lexaria Bioscience aprovam eleição do conselho e auditor em assembleia anual

Lexaria Bioscience shareholders approve board elections and auditor at annual meeting

Tecnologia DehydraTECH da Lexaria mostra redução de efeitos colaterais em medicamentos GLP-1

Lexaria’s DehydraTECH shows reduced side effects in GLP-1 drugs

Why Bark Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket - Abivax (NASDAQ:ABVX), Rich Sparkle Holdings (NASDAQ:ANPA)

Capital One Financial To Rally More Than 24%? Here Are Top Analyst Forecasts For Friday - Agios Pharmaceuticals (NASDAQ:AGIO), Capital One Finl (NYSE:COF)

Preço-alvo das ações da Lexaria Bioscience reduzido para US$ 1,50

Lexaria Bioscience stock price target cut to $1.50 from $4 at H.C. Wainwright

DehydraTECH-semaglutida mostra 48% menos efeitos colaterais que Rybelsus

DehydraTECH-semaglutide shows 48% fewer side effects than Rybelsus

Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus - Lexaria Bioscience (NASDAQ:LEXX)

Lexaria Bioscience closes $3.5 million registered direct offering